myLotus® pregnancies in double figures

RNS Number : 8693E

Concepta PLC

09 July 2019

 

Concepta announces myLotus® pregnancies in double figures  

Concepta PLC (AIM: CPT), the innovative UK personalised healthcare company and developer of the proprietary self-test platform ("myLotus®") and suite of emerging test products targeting the mobile health market with a primary focus on women's fertility and hormone health announces today its myLotus® user pregnancies have now moved into double figures. The first myLotus® 'live births' are expected later this year. User testimonials for the myLotus® monitor and app remain exceptional with many users providing personal video feedback and testimonials on their menstrual cycle hormone changes and profiles ('signatures') to enable other women to better understand their fertility journey (www.mylotus.com)

myLotus® the revolutionary home based, self-test product was launched in the UK in November 2018 with the first wave of users being women who had historically struggled to fall pregnant (some after many years of 'trying to conceive') after using traditional less responsive fertility tests. myLotus® provides a technically advanced quantitative test applicable to 100% of women.  

The myLotus® device empowers women to self-test their personalised hormone levels and identify their optimal fertile days thereby improving their chances of a natural pregnancy. myLotus® enables women to monitor their fertile phase as part of their menstrual cycle and is the only home test to 'quantitatively' measure hormone levels and the 'rate-of-change' of these levels preceding ovulation thereby providing greater accuracy and timing of intercourse to deliver a natural conception. Users measure, record and accurately track their hormone levels and follow their fertility journey in an accompanying free downloadable app available in iOS and Android formats via the  www.mylotus.com website.

In March the Company announced its first supply agreement with Boots UK (part of Walgreens Boots Alliance) where sales continue to build. The Company anticipates further B2B announcements over the coming months.   

myLotus® is available to women who are planning to start a family or for those who have previously struggled to naturally conceive, enabling couples a cost effective and technically leading alternative prior to considering more costly IVF treatment. The Company expects to release further hormone health and wellbeing tests to complement its fertility offering later this year.        

Matthew Walls, Chairman said: "We are extremely proud and delighted to announce the growing number of pregnancies and look forward to our first myLotus® 'live births' later this year. Whilst our marketing and brand profile are nascent our early pregnancy statistics are impressive. Following the recent myLotus® launch our first wave of users are women who have struggled to conceive naturally, some after trying for many years. These women and their testimonials are now providing  real world evidence of the value of the myLotus® technology as a breakthrough in helping women increase their chances of a natural pregnancy. We understand the difficulties and emotions involved in trying to conceive and look forward to supporting all our users on their pregnancy journey. This note provides a short update to advise on our strengthening Company developments."

Enquiries

Company: www.conceptaplc.com, Product: www.mylotus.com

Matthew Walls, Chairman

Tel: [phone]

SPARK Advisory Partners Limited (Nomad)

Neil Baldwin

Tel: [phone]

Novum Securities

Colin Rowbury

[phone]

About Concepta PLC:

Concepta Plc is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus®, targeting the personalised mobile health market with a primary focus on hormone testing and increasing a woman's chances of a natural pregnancy and to provide insight to unexplained infertility.

myLotus® is currently the only consumer product which allows both quantitative and qualitative home (self-test) test measurement of a woman's personal luteinizing hormone (LH) during ovulation and human chorionic gonadotropin (hCG) hormone level during pregnancy, facilitating higher conception rates and early diagnosis of fertility issues. The proposition of myLotus® is to empower women to better understand their hormone levels and menstrual cycle and help women conceive naturally by identifying their window of fertility and optimal time for conception.

The Company has received CE-mark certification for myLotus® and recently launched its first product in the UK. The Company is preparing plans to roll-out across the core EU countries in 2019.

myLotus® is expected to be beneficial to users who have been unable to naturally conceive after some months of trying. This highly motivated target group of women won't typically be offered medical intervention until after 12 months of unsuccessfully trying to conceive, with IVF not usually offered until after two years of trying to conceive. Research indicates couples start to take positive action ahead of this time typically with little medical support to help them do so.

 

END

 

 

MSCCKFDNBBKBBOK